Afatinib in Treatment-Naive Patients With EGFR-Mutated Lung Adenocarcinoma With Brain Metastasis: A Case Series

Tyrosine kinase inhibitors (TKIs) of epidermal growth factor receptor (EGFR) were previously the standard first-line treatments for lung cancers with activating EGFR mutations. The first-generation reversible EGFR TKIs, gefitinib and erlotinib, demonstrated substantial efficacy in the treatment of b...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Shih-Hong, Hsieh, Meng-Heng, Fang, Yueh-Fu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2015
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4616807/
https://www.ncbi.nlm.nih.gov/pubmed/26469914
http://dx.doi.org/10.1097/MD.0000000000001739

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4616807/
https://www.ncbi.nlm.nih.gov/pubmed/26469914
http://dx.doi.org/10.1097/MD.0000000000001739

Ejemplares similares